Aus Pubmed

J Clin Aesthet Dermatol. 2024 Oct;17(10):19-22. ABSTRACT OBJECTIVE: We sought to correlate the time lag between psoriatic arthritis (PsA) symptom onset and diagnosis to the likelihood and severity of depression, social impairment, and disease impact on quality of life. METHODS: This cross-sectional study conducted by the National Psoriasis Foundation (NPF) surveyed individuals with PsA using patient-reported outcome measures. RESULTS: The analysis cohort comprised 2,196 patients with PsA. Likeli

RMD Open. 2024 Oct 22;10(4):e004699. doi: 10.1136/rmdopen-2024-004699. ABSTRACT OBJECTIVES: The widespread adoption of wearables, for example, smartphones and smartwatches in the daily lives of the general population, allows passive monitoring of physiological and behavioural data in the real world. This qualitative study explores the perspective of psoriatic arthritis (PsA) patients towards these so-called digital biomarkers (dBMs). METHODS: As part of a Design Thinking approach, six focus grou

Rheumatol Int. 2024 Apr 10. doi: 10.1007/s00296-024-05576-7. Online ahead of print. ABSTRACT Global health (GH) and health-related quality of life are patient priorities in axial spondyloarthritis (axSpA). Our objective was to assess the relative importance of disease-related factors including disease activity, and patient-related factors including comorbidities, to explain GH in axSpA. Post hoc cross-sectional analyses of 4 sets (COMOSPA, PERSPA, COMEDSPA, and DESIR) of patients fulfilling ASAS

Front Immunol. 2024 May 23;15:1410540. doi: 10.3389/fimmu.2024.1410540. eCollection 2024. ABSTRACT Psoriasis is a common, life-long skin disease with a significant negative health and societal impact. Data on rates of disease control and treatment strategies are lacking in Central and Eastern European countries. We aimed to describe the real-world disease severity, control, and treatment strategies for psoriasis in patients from Central and Eastern European countries. CRYSTAL (EUPAS36459) was a

J Autoimmun. 2025 Jan 11;151:103357. doi: 10.1016/j.jaut.2025.103357. Online ahead of print. ABSTRACT Regulatory T cell (Treg) play a pivotal role in immune regulation and maintaining host immune homeostasis. Treg heterogeneity, characterized by diverse gene expression profiles and functional states, is complex in both health and disease. Research reveals that Tregs are not a uniform population but exhibit diversity based on their origin, location, and functional status. This heterogeneity is cr

Exp Dermatol. 2024 May;33(5):e15067. doi: 10.1111/exd.15067. ABSTRACT Patients receiving interleukin (IL)-inhibiting biologics for moderate-to-severe psoriasis (PsO) may be treated with escalated doses to optimize outcomes. This study evaluated escalation prevalence in a Japanese claims analysis of patients with PsO diagnosis preceding IL-inhibiting biologic treatment and ≥1 post-induction maintenance claim (index date) with sufficient data availability from January 2014 to May 2022. Patients wi

Front Pharmacol. 2024 Mar 28;15:1369805. doi: 10.3389/fphar.2024.1369805. eCollection 2024. ABSTRACT Dose reduction (DR) of first-generation biologics for plaque psoriasis (TNF-alpha inhibitors (i) and interleukin (IL)-12/23i) has been described in a previous scoping review. The literature on the DR of the newest generation of biologics (IL-17/23i) was scarce. The current review provides a literature update on the previous scoping review on the DR of all biologics, including the newest generatio

Acad Pathol. 2024 Dec 11;12(1):100154. doi: 10.1016/j.acpath.2024.100154. eCollection 2025 Jan-Mar. NO ABSTRACT PMID:39758588 | PMC:PMC11697160 | DOI:10.1016/j.acpath.2024.100154 Den ganzen Artikel lesen

Arch Dermatol Res. 2024 Jun 8;316(7):362. doi: 10.1007/s00403-024-03122-w. ABSTRACT Secukinumab is a fully human IgG1 antibody that selectively binds to and neutralizes the proinflammatory cytokine interleukin-17A. Secukinumab is an effective and well-tolerated treatment for plaque psoriasis. There is a limited real-word evidence for dose optimisation of secukinumab based on clinical response. PURE is a multi-national, prospective, observational study in patients with moderate to severe chronic

J Dermatolog Treat. 2024 Dec;35(1):2420825. doi: 10.1080/09546634.2024.2420825. Epub 2024 Oct 27. ABSTRACT Introduction: Psoriasis is a chronic immune-mediated disease that can be challenging to treat, especially in patients with severe disease or high body weight. Tildrakizumab is a monoclonal antibody which inhibits IL-23, approved for moderate-to-severe psoriasis with a standard 100 mg dose. A 200 mg dose may provide greater efficacy for patients over 90 kg or with high disease burden. Method

Ther Adv Musculoskelet Dis. 2025 Jan 31;17:1759720X251315138. doi: 10.1177/1759720X251315138. eCollection 2025. ABSTRACT BACKGROUND: Randomized clinical trials have demonstrated the efficacy of secukinumab (SECU) in reducing disease activity in psoriatic arthritis (PsA), while real-world studies prove a broader perspective on SECU's usefulness in everyday clinical practice. OBJECTIVES: To assess the effectiveness of SECU by evaluating drug survival and identifying potential predictors of clinica

Br J Dermatol. 2024 Sep 30:ljae370. doi: 10.1093/bjd/ljae370. Online ahead of print. NO ABSTRACT PMID:39344069 | DOI:10.1093/bjd/ljae370 Den ganzen Artikel lesen

Expert Opin Drug Saf. 2024 May 3. doi: 10.1080/14740338.2024.2351462. Online ahead of print. ABSTRACT INTRODUCTION: Nowadays, despite the wide availability of biological drugs and apremilast for psoriasis management, there is always a need for new therapies to customize the therapeutic approach on the basis of the patient's clinical features and comorbidities, especially in order to achieve a prolonged therapeutic response. Thus, new treatment strategies are required to offer patients a personal

Br J Dermatol. 2024 Oct 23:ljae402. doi: 10.1093/bjd/ljae402. Online ahead of print. ABSTRACT BACKGROUND: ABP 654 is a biosimilar to ustekinumab reference product (RP). ABP 654 has been shown to have an amino acid sequence identical to ustekinumab RP and they are similar in structure, purity, and potency as well as clinical pharmacokinetics and safety in healthy volunteers. OBJECTIVES: This randomized, double-blinded, active-controlled, single-transition, comparative clinical study (ClinicalTria

Adv Ther. 2024 Sep 30. doi: 10.1007/s12325-024-02976-w. Online ahead of print. ABSTRACT INTRODUCTION: Special body area involvement is common in psoriasis and can be challenging to treat. We investigated the efficacy of ixekizumab (IXE) in Chinese patients with moderate-to-severe psoriasis and fingernail, scalp, or palmoplantar involvement. METHODS: A post-hoc sub-analysis of a phase 3 trial, in which patients were randomized to receive placebo, IXE 80 mg every 2 (IXE Q2W) or 4 (IXE Q4W) weeks.

Dermatol Reports. 2025 Feb 6;17(1). doi: 10.4081/dr.2024.9999. Epub 2024 Aug 9. ABSTRACT Psoriasis is an inflammatory chronic disease of the skin, typically located on the extensor surfaces of the body and the trunk. Patients with psoriasis can often present multiple characteristics, such as lesions located in difficult-to-treat (DTT) areas or high severity of the disease, which can negatively affect their quality of life. There is a lack of consensus in identifying the best therapy for these co

Sci Rep. 2024 Apr 27;14(1):9715. doi: 10.1038/s41598-024-60526-4. ABSTRACT The tendency of skin diseases to manifest in a unique and yet similar appearance, absence of enough competent dermatologists, and urgency of diagnosis and classification on time and accurately, makes the need of machine aided diagnosis blatant. This study is conducted with the purpose of broadening the research in skin disease diagnosis with computer by traversing the capabilities of deep Learning algorithms to classify t

Endocrinol Diabetes Metab. 2024 May;7(3):e00476. doi: 10.1002/edm2.476. ABSTRACT OBJECTIVE: Onset and exacerbation of autoimmune, inflammatory or steroid-responsive conditions have been reported following the remission of Cushing syndrome, leading to challenges in distinguishing a new condition versus expected symptomatology following remission. We describe a case of a 42-year-old man presenting with new-onset sarcoidosis diagnosed 12 months following the surgical cure of Cushing syndrome and sy

Theranostics. 2024 May 27;14(8):3339-3357. doi: 10.7150/thno.93764. eCollection 2024. ABSTRACT Rationale: Skin cells actively metabolize nutrients to ensure cell proliferation and differentiation. Psoriasis is an immune-disorder-related skin disease with hyperproliferation in epidermal keratinocytes and is increasingly recognized to be associated with metabolic disturbance. However, the metabolic adaptations and underlying mechanisms of epidermal hyperproliferation in psoriatic skin remain large

RSC Med Chem. 2025 Jan 2. doi: 10.1039/d4md00781f. Online ahead of print. ABSTRACT Topical delivery of therapeutics on the skin can effectively alleviate skin symptoms of psoriasis and reduce systemic toxicity. However, the low delivery efficiency caused by the stratum corneum barrier limits the therapeutic impact. Here, we reported an oligopeptide hydrogel that encapsulates cell-penetrating-peptide (CPP)-decorated curcumin-loaded nanoemulsions (Cur-CNEs) to enhance the skin penetration of curcu

Am J Psychother. 2024 Sep 30:appipsychotherapy20230061. doi: 10.1176/appi.psychotherapy.20230061. Online ahead of print. ABSTRACT Epigenetic modifications play a pivotal role in the regulation of gene expression and cell function, offering potential markers of disease states and therapeutic outcomes. Recent advancements in neuroscience have spurred interest in studying the epigenetic underpinnings of psychosomatic medicine. This review presents a new perspective on the role of epigenetic regulat

Mult Scler. 2024 Oct 22:13524585241290986. doi: 10.1177/13524585241290986. Online ahead of print. NO ABSTRACT PMID:39435541 | DOI:10.1177/13524585241290986 Den ganzen Artikel lesen

Diabetes Metab Syndr. 2025 Jan 7;19(1):103186. doi: 10.1016/j.dsx.2025.103186. Online ahead of print. ABSTRACT OBJECTIVE: To investigate the causal association of using glucagon-like peptide-1 receptor (GLP1R) agonists with autoimmune diseases. METHODS: The available cis-eQTLs for drugs target genes (GLP1R) were used as genetic variants for exposure to GLP1R agonists. Type 2 diabetes was used as positive control. Mendelian randomizations (MR) were performed to explore the association of genetica

Arch Dermatol Res. 2025 Jan 18;317(1):282. doi: 10.1007/s00403-024-03676-9. ABSTRACT One of the most frequently impacted locations by psoriasis is the scalp. It is seen in about 80% of psoriasis cases worldwide, and its treatment is challenging. To compare the efficacy and safety of excimer light versus topical methotrexate (MTX) 1% hydrogel in treatment of scalp psoriasis. This randomized prospective intra-patient comparative study was carried out on 30 patients with scalp psoriasis. Lesions we

Cutis. 2024 Feb;113(2):82-91. doi: 10.12788/cutis.0949. ABSTRACT Psoriasis is a chronic heterogeneous condition with multiple available treatment options that have resulted in dramatic disease improvements for patients. IL-23/IL-17 signaling is the central immune signaling pathway driving psoriasis, though recent research has uncovered other key contributing signals such as IL-17C, IL-17F, IL-36, and tyrosine kinase 2 (TYK2). Novel therapeutic targets inhibiting these cytokines have expanded our